Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06679101 · ClinicalTrials.gov registry record · Phase 3

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

A Phase 3 study of Multiple Myeloma and Newly Diagnosed Multiple Myeloma, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 3
Development phase
520
Enrollment target
20
Study locations

NCT06679101: Recruiting Phase 3 study of Multiple Myeloma and Newly Diagnosed Multiple Myeloma, sponsored by GlaxoSmithKline.

NCT06679101 is a Phase 3 study of Multiple Myeloma and Newly Diagnosed Multiple Myeloma that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 520 participants, roughly in line with the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06679101, a Phase 3 study of Multiple Myeloma and Newly Diagnosed Multiple Myeloma, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 3
Development phase
520 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

Primary Outcome

Defined as the time from the date of randomization to the date of first documented PD per International Myeloma Working Group (IMWG) criteria by Independent Review Committee (IRC) or death from any cause in the absence of progression, whichever occurs first.

Conditions Studied

Multiple Myeloma Newly Diagnosed Multiple Myeloma

Interventions

  • DRUG Belantamab mafodotin
  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Daratumumab

Study Locations (20)

Florida

  • GSK Investigational Site - Englewood
  • GSK Investigational Site - Lady Lake
  • GSK Investigational Site - Pembroke Pines
  • GSK Investigational Site - Saint Augustine

California

  • GSK Investigational Site - Beverly Hills
  • GSK Investigational Site - Pasadena

North Carolina

  • GSK Investigational Site - Charlotte
  • GSK Investigational Site - Winston-Salem

Alabama

  • GSK Investigational Site - Mobile

Arizona

  • GSK Investigational Site - Phoenix

Colorado

  • GSK Investigational Site - Aurora

Georgia

  • GSK Investigational Site - Atlanta

Maine

  • GSK Investigational Site - Portland

Trial Details

FieldValue
Enrollment Target 520 participants
Start Date 2024-12-16
Est. Completion 2031-03-31
Phase Phase 3
GlaxoSmithKline

1,345 total trials

What NCT06679101 shows while recruiting

NCT06679101 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target.

The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Belantamab mafodotin is the first listed.

NCT06679101 names 20 study sites across 15 states, led by Florida, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06679101 about?

NCT06679101 is a clinical study titled "A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)". The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

What is the current status of trial NCT06679101?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2024-12-16. Estimated completion is 2031-03-31.

What conditions does trial NCT06679101 study?

This clinical trial studies the following conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma.

What interventions are being tested in trial NCT06679101?

The interventions under investigation include: Belantamab mafodotin (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG).

Who is sponsoring clinical trial NCT06679101?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06679101 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06679101's enrollment target sits among peer trials

520 41st of 438 higher than 398 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323581 · 520 participants · NA

    Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts

  • NCT04656496 · 520 participants · NA

    NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors

  • NCT05445778 · 520 participants · Phase 3

    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

  • NCT05498428 · 520 participants · Phase 2

    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06679101

Source: ClinicalTrials.gov NCT06679101, the US trial registry maintained by the National Library of Medicine. NCT06679101 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.